| CAS ID: | 134523-00-5 |
| Molecular Formula: | C33H35FN2O5 |
| Molecular Weight: | 558.7 g/mol |
| Monoisotopic Mass: | 558.253 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | LIPITOR | SORTIS | ATORVASTATIN CALCIUM | TAHOR | PREVENCOR | CARDYL | ATORVASTATIN | ZARATOR | CI-981 |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 | See All |
| InChI Key: | XUKUURHRXDUEBC-KAYWLYCHSA-N | |
| Smiles: | CC(C)c1c(C(=O)Nc2ccccc2)c(c3ccccc3)c(c4ccc(F)cc4)n1CC[C@@H](O)C[C@@H](O)CC(=O)O | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 27830000 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 2
| PubMed ID | 24351828 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Idiopathic pulmonary fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | Targeting iNOS and CTGF (CCN2)/ERK signaling | ||
Reference Record 3
| PubMed ID | 15466656 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,mice | Fibrosis Disease | Cardiac fibrosis |
| Process I | |||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 4
| PubMed ID | 24161914 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Pulmonary fibrosis |
| Process I | |||
| Process II | fibroblasts accumulation | ||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 5
| PubMed ID | 21570962 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Reference Record 6
| PubMed ID | 17589825 | Target ID | |
| Uniprot ID | Name | ||
| Model | rat | Fibrosis Disease | Cardiac fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT00795912 | Disease | Cardiac fibrosis |
| Phase | Phase 4 | Status | Completed |
| First Received | November 21, 2008 | Last Verified | November 21, 2008 |
| Sponsor | St Vincent's University Hospital, Ireland | ||
Trial Record 2
| ClinicalTrial ID | NCT00844402 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | February 16, 2009 | Last Verified | February 16, 2009 |
| Sponsor | Medical University of Graz | ||
Trial Record 3
| ClinicalTrial ID | NCT01987310 | Disease | Liver fibrosis |
| Phase | Not Applicable | Status | Withdrawn |
| First Received | November 19, 2013 | Last Verified | April 27, 2017 |
| Sponsor | Sheba Medical Center | ||
| PubChem: | 60823 |
| ChEMBL: | CHEMBL1487 |